Isofol’s partner Solasia intends to increase investments in upcoming trials with arfolitixorin
GOTHENBURG, Sweden, April 3, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces that the company’s Japanese development and […]
Corporate Information
Isofol etablishes advisory board with leading experts
GOTHENBURG, Sweden, March 27, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has established
Isofol receives regulatory approval to initiate clinical study of arfolitixorin
GOTHENBURG, Sweden, March 21, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the regulatory authority in
Isofol expands network of advisors with prominent expert
GOTHENBURG, Sweden, March 17, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has expanded
Isofol presents at Stora Aktiedagarna on March 12
GOTHENBURG, Sweden, March 12, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces that the company’s CEO will present
Isofol presents at several upcoming investor meetings
GOTHENBURG, Sweden, March 5, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces that the company will participate in
Isofol appoints Roger Tell as Chief Medical Officer ahead of initiation of clinical study
GOTHENBURG, Sweden, February 3, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that Roger Tell has been
Isofol announces the presentation of a post-hoc analysis of the phase III study AGENT at the 2025 ASCO GI symposium
GOTHENBURG, Sweden, January 27, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that an abstract of the
Isofol and its partner Solasia plan to expand the upcoming clinical trial of arfolitixorin to Japan
GOTHENBURG, Sweden, December 18, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that its partner Solasia Pharma
Isofol announces that an investigator-initiated study of arfolitixorin has been published in BJC Reports
GOTHENBURG, Sweden, November 21, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that the investigator-initiated Modelle study,